A 3 adenosine receptor: A plausible therapeutic target for cardio-protection in diabetes

Recent Patents on Cardiovascular Drug Discovery

Volumn 7, Issue 1, 2012, Pages 59-70

  Nishat, Shamama ^a   Shabir, Hiba ^b   Azmi, Asfar S ^b   Ansari, Habib R ^a,b  

^a JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

A 3 Adenosine receptor; Cardiovascular complications; Diabetes; Heart

Indexed keywords

2 (2 HYDROXYETHYL) 1 [3 (2 PHENYLPYRAZOLO[1,5 A]PYRIDIN 3 YL)ACRYLOYL]PIPERIDINE; 2 CHLORO 6 N CYCLOPENTYLADENOSINE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 4 [7 [[1 [(3 CHLORO 2 THIENYL)METHYL]PROPYL]AMINO] 3H IMIDAZO[4,5 B]PYRIDIN 3 YL] N ETHYL 2,3 DIHYDROXYCYCLOPENTANECARBOXAMIDE; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5 AMINO 2 (2 FURYL) 7 [3 (4 METHOXYPHENYL)PROPYL]PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 6 ETHYL 2 PHENYL 4 PROPYL 3 PYRIDINECARBOXYLIC ACID 5 THIOCARBOXYLIC ACID 5 ETHYL 3 PROPYL ESTER; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; CP 608039; CV 3146; EP 1758596B9; EP 2221307A1; FR 194921; ISTRADEFYLLINE; MRS 1292; MRS 1334; MRS 1898; MRS 3558; MRS 3777; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; NAXIFYLLINE; OSIP 339391; OT 7999; PSB 11; ROLOFYLLINE; TONAPOFYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; US 20110003845A1; US 7825126; VER 6947; VER 7835; WO 2008058238A2; WO 2009076580A2; WO 2011068978A1;

ANGINA PECTORIS; CACHEXIA; CALCIUM SIGNALING; CELL PROLIFERATION; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETIC RETINOPATHY; DRUG TARGETING; EDEMA; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REPERFUSION INJURY; REVIEW; SMOOTH MUSCLE FIBER; WASTING SYNDROME;

ADENOSINE A3 RECEPTOR AGONISTS; ADENOSINE A3 RECEPTOR ANTAGONISTS; ANIMALS; CARDIOTONIC AGENTS; DIABETES MELLITUS; HEART DISEASES; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, ADENOSINE A3;

EID: 84857750489     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489012799362421     Document Type: Review

References (153)

1. Rother KI. Diabetes treatment -bridging the divide. N Engl J Med 2007; 356: (15): 1499-501.
2. Tierney LM, McPhee SJ, Papadakis MA. Current medical Diagnosis & Treatment. International edition. New York: Lange Medical Books/McGraw-Hill 2002.
3. Guyton AC, Hall JE. Textbook of Medical Physiology. 11th ed. SAUNDERS: An imprint of Elsevier; 2006.
4. Laurent M, Hillarie-Buys D, Chapal J, Dietz S, Portet K, Gros G, Michel A. Contrasting effects of streptozotocin-induced diabetes on the in vitro relaxant properties of adenosine in rat pancreatic vascular bed and thoracic aorta. Naunyn-Schmiedeberg's Arch Pharmacol 1999; 360: 309-16.
5. Raptis S. Hypertension and diabetics mellitus. In: Rosenthan, J. Ed. Arterial hypertension. Springer: New York 1982.
6. Azevedo I, Osswald W. Does adenosine malfunction plays a role in hypertension? Pharmacol Res 1992; 25: 227-36.
7. Dai S, McNeill JH. Myocardial performance of STZ-diabetic DOCA-hypertensive rats. Am J Physiol Heart Circ Physiol 1992; 263: H1798-805.
8. Garvey ST, Hardin HD, Juhaszova M, Dominiguez JH. Effects of diabetes on myocardial glucose transport system in rats: Implications for diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 1993; 264: H837-H844.
9. Mayhan WG. Impairment of endothelium-dependent dilatation of the basilar artery during diabetes mellitus. Brain Res 1992; 58: 297-302.
10. Pieper GM, Gross G. Oxygen-derived free radicals abolish Endothelium dependent relaxation in diabetic rat aorta. Am J Physiol Heart Circ Physiol 1988; 255: H825-H33.
11. Ruderman NB, Haudenschild C. Diabetes as an atherogenic factor. Prog Cardiovasc Res 1984; 26: 373-412.
12. 2. Am J Physiol 1989; 257: H1327-33.
13. Bell DS. Hypertension in the person with diabetes. Am J Med Sci 1989; 297: 228-32.
14. Fein FS, Zola E, Malhotra A, Cho S, Factor SM, Scheuer J, et al. Hypertensive-diabetic cardiomyopathy in rats. Am J Physiol Heart Circ Physiol 1990; 258: H793-H805.
15. Poston L, Taylor PD. Endothelium-mediated vascular function in insulin-dependent diabetes mellitus. Clin Sci 1995; 88: 245-55.
16. Koivisto VA, Stevens LK, Mattock M, Ebeling P, Muggeo M, Stephenson J, et al. Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. Diabetes Care 1996; 19: 689-97. 283: H1307-H1313.
17. Feener EP, King GL. Vascular dysfunction in diabetes mellitus. Lancet 1997; 350: 9-13.
18. Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY, Smithline KL, et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes:10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2003; 26: 1374-9.
19. Taegtmayer H, McNutty P, Young ME. Adaptation and maladaptation of the heart in diabetes: Part 1, General concepts. Circulation 2002; 105: 1727-33.
20. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type1 diabetes. N Engl J Med 2005; 353: 2643-53.
21. Hayat SA, Patel B, Khattar RS, Malik RA. Diabetic cardiomayopathy: Mechanism, diagnostics and treatment. Clinical Sciences 2004; 107: 539-57.
22. Pawelczyk T, Podgorsaka M, Sakowicz M. The effect of insulin on expression level of nucleoside transporter in diabetic rats. Mol Pharmacy 2003; 63: 81-8.
23. Hask G, Cronstein BN. Adenosine: An endogenous regulator of innate immunity. Trends Immunol 2004; 25: 33-39.
24. Tabrizchi R, Bedi S. Pharmacology of adenosine receptors in the vasculature. Pharmacol Ther 2001; 91:133-47.
25. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001; 53: 527-52
26. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nature Rev Drug Discov 2006; 247-64.
27. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998; 50: 413-92.
28. 1 receptor in the cat esophageal smooth muscle cells. Cell Signal 2002; 14: 365-72.
29. Yang SJ, An JY, Shim JO, Park CH, Huh IH, Sohn UD. The mechanism of contraction by 2-chloroadenosine in cat detrusor muscle cells. J Urol 2000; 163: 652-8.
30. Biaggioni I. Contrasting excitatory and inhibitory effects of Adenosine in blood pressure regulation. Hypertension 1992; 20: 457-65.
31. Fahim M, Hussain T, Mustafa SJ. Relaxation of rat aorta by adenosine in diabetes with and without hypertension; role of endothelium. Eur J Pharmacol 2001; 412: 51-9.
32. 1-receptors in caudal arteries of spontaneous hypertensive rats. Eur J Pharmacol 1989; 174: 237-51.
33. 1 adenosine receptor-mediated PKC and p42/p44 MAPK signaling in mouse coronary artery smooth muscle cells. Am J Physiol Heart Circ Physiol 2009; 297: H1032-H1039.
34. Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: Therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008; 7: 759-70.
35. Olsson RA, Pearson JD. Cardiovascular purinoceptors. Physiol Rev 1990; 70: 761-845.
36. 1 receptor overexpression. Clin Exp Pharmacol Physiol 2000; 27: 185-90.
37. 1 adenosine receptors. J Mol Cell Cardiol 1998; 30: 187-93.
38. 1 receptors. Acta Physiol (Oxf) 2007; 190: 63-75.
39. 1 adenosine receptor limits myocardial ischemic tolerance. Circ Res 2005; 96: 363-7.
40. 1 adenosine receptorabolishes heart-rate slowing effects of intravascular adenosine in vivo. PLoS One 2009.
41. Dolphin AC, Forda SR, Scott RH. Calcium-dependent currents in cultured rat dorsal root ganglion neurones are inhibited by an adenosine analogue. J Physiol 1986; 373: 47-61.
42. Burgdorf C, Richardt D, Kurz T, Seyfarth M, Jain D, Katus HA, et al. Adenosine inhibit norepinephrine release in the postischemic rat heart: the mechanism of neuronal stunning. Cardiovasc Res 2001; 49:713-20.
43. 1-receptors. J Cardiovasc Pharmacol 2005; 45:1-3.
44. 1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis. US20030212082 (2003).
45. 2+ entry and endothelial hyper permeability. Circ Res 2008; 102: 347-55.
46. 1- receptors. J Immunol 1993; 151: 2775-85.
47. McKusick VA. Mendelian inheritance in man. A catalog of human genes and genetic disorders. Baltimore: Johns Hopkins Univ Press 2006.
48. Xu Z, Park S-S, Mueller RA, Bagnell RC, Patterson C, Boysen PG. Adenosine produces nitric oxide and prevents mitochondrial oxidant damage in rat cardiomyocytes. Cardiovasc Res 2005; 65: 803-12.
49. 2 receptor activation at reperfusion. J Cardiovasc Pharmacol 2005; 46:794-802.
50. Yonehana T, Gemba M. Ameliorative effect of adenosine on hypoxia-reoxygenation injury in LLC-PK1, a porcine kidney cell line. Jpn J Pharmacol 1999; 80: 163-7.
51. Zhang W, Liu H, Rojas M, Caldwell RW, Caldwell RB. Antiinflammatory therapy for diabetic retinopathy. Immunotherapy 2011; 3: 609-8.
52. 2A receptor gene are protective against proliferative diabetic retinopathy in patients with type 1 diabetes. Ophthalmic Res 2011; 46:1-8.
53. Fleck BW, McIntosh N. Pathogenesis of retinopathy of prematurity and possible preventive strategies. Early Hum Dev 2008; 84: 83-8.
54. Ibrahim AS, El-Shishtawy MM, Zhang W, Caldwell RB, Liou GI. A(2A) adenosine receptor (A(2A)AR) as a therapeutic target in diabetic retinopathy. Am J Pathol 2011; 178: 2136-45.
55. 2A adenosine receptor inhibits inflammation in a rat model of meningitis: Synergy with the type IV phosphodiesterase inhibitor, rolipram. J Infect Dis 1999; 180: 1550-60.
56. 2A adenosine receptor agonists. J Med Chem 2001; 44: 531-9.
57. Linden J. Molecular approach to adenosine receptors: Receptormediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 2001; 41: 775-87.
58. 2A receptors inhibits IL-12 production by human monocytes. J Immunol 2000; 164: 436-42.
59. Cushing DJ, Brown GL, Sabouni MH, Mustafa SJ. Adenosine receptor-mediated coronary artery. Am J Physiol 1991; 261: H1848-54.
60. 2 receptor agonists CGS 21680 and CGS 22492 in human vasculature. Eur J Pharmacol 1992; 222: 243-7.
61. Prentice DJ, Hourani SM. Activation of multiple sites byadenosine analogues in the rat isolated aorta. Br J Pharmacol 1996; 1186: 1509-17.
62. 2A receptors. Trends Pharmacol Sci 1996; 17: 364-72.
63. Abebe W, Hussain T, Olanrewaju H, Mustafa SJ. Role of nitric oxide in adenosine receptor-mediated relaxation of porcine coronary artery. Am J Physiol Heart Circ Physiol 1995; 269: H1672-H78.
64. 2 receptors in regulation of cerebral blood flow during induced hypotension. J Cerebral Blood Flow Metab 2010; 30: 808-15.
65. Kin H, Zatta AJ, Lofye MT, Amerson BS, Halkos ME, Kerendi F, et al. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res 2005; 67:124-33.
66. 2+ pathway. Circ Res 2006; 99: 590-7
67. 2A adenosine receptor deficiency leads to impaired tracheal relaxation via NADPH oxidase pathway in allergic mice. J Pharmacol Exp Ther 2009; 330: 99-108.
68. 2A receptor antagonist SCH 58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia. Brain Res 2006; 1073-1074: 470-80.
69. 2A receptor signaling regulation of cardiac NADPH oxidase activity. Free Radic Biol Med 2008; 44:1433-42.
70. Park L, Anrather J, Zhou P, Frys K, Pitstick R, Younkin S, et al. NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide J. Neurosci 2005; 25: 1769-77.
71. 2A receptor protects apolipoprotein E-deficient mice from atherosclerosis. Arterioscler Thromb Vasc Biol 2009; 29: 1046-52.
72. 3 adenosine receptor-mediated protection of the ischemic heart. Vascul Pharmacol 2005; 42: 271-9.
73. 3 adenosine receptors with N6- (3-iodobenzyl) adenosine-5'-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circ Res 1997; 80: 800-9.
74. 3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart. Cardiovasc Res 1997; 33: 410-15.
75. 3 pretreatment before cardioplegic arrest attenuates postischemic cardiac dysfunction. Ann Thorac Surg 1999; 67: 1732-7.
76. 3 adenosine receptor. J Pharmacol Exp Ther 2006; 319: 1200-10.
77. Xu Z, Jang Y, Mueller RA, Norfleet EA. IB-MECA and cardioprotection. Cardiovasc Drug Rev 2006; 24: 227-38.
78. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801-9.
79. Colwell JA and Lopes-Virella MF. A review of the development of large vessel disease in diabetes mellitus. Am J Med 1988; 85: 13-18.
80. Kawano M, Koshikawa T, Kanzaki T, Morisaki N, Saito Y, Yoshida S. Diabetes mellitus induces accelerated growth of aortic smooth muscle cells: association with overexpression of PDGF beta-receptors. Eur J Clin Invest 1993; 23: 84-90.
81. Jonzon B, Nilsson J, Fredholm BB. Adenosine receptor-mediated changes in cyclic AMP production and DNA synthesis in cultured arterial smooth muscle cells. J Cell Physiol 1985; 124: 451-6.
82. Pares-Herbute N, Hillaire-Buys D, Etienne P, Gross R, Loubatieres- Mariani MM, Monnier L. Adenosine inhibitory effect on enhanced growth of aortic smooth muscle cells from streptozotocininduced diabetic rat. Brit J Pharmacol 1996; 118: 783-9.
83. Grden M, Podgorska M, Szutowicz A, Pawelczyk T. Altered expression of adenosine receptors in the heart of diabetic rat. J Physiol Pharmacol 2005; 56: 587-97.
84. Zoltán HN, David B, Balázs C, Pál P, Jon GM, Leonóra H, et al. Adenosine receptor activation ameliorates type 1 diabetes. FASEB J 2007; 21: 2379-88.
85. 3 adenosine receptor-mediated contraction through endothelium in mice aorta. Am J Physiol Heart Circ Physiol 2007; 293: H3448-55.
86. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J 1989; 3: 2007-17.
87. Vanhoutte PM, Feletou M, Taddei S. Endothelium-dependent contractions in hypertension. Br J Pharmacol 2005; 144: 477-85.
88. 2 as endothelium-derived contracting factors. Am J Physiol Heart Circ Physiol 2006; 291: H2255-H2264.
89. Schiffrin EL. A critical review of the role of endothelial factors in the pathogenesis of hypertension. J Cardiovasc Pharmacol 2001; 38: S3-S6.
90. Yang D, Feletou M, Boulanger CM, Wu HF, Levens N, Zhang JN, Vanhoutte PM. Oxygen-derived free radicals mediate endothelium dependent contractions to acetylecholine in aortas from spaontaneously hypertensive rats. Br J Pharmacol 2002; 136: 104-10.
91. Breyer MD, Breyer RM. G protein-coupled prostanoid receptors and the kidney. Annu Rev Physiol 2001; 63: 579-605.
92. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: Structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69: 145-82.
93. 3 receptors augments adenosine-induced coronary flow in isolated mouse heart. Am J Physiol Heart Circ Physiol 2002; 282: H2183-H29.
94. 3 adenosine receptor. Circ Res 1996; 78: 627-34.
95. 3 receptor reverses vascular hyporeactivity after hemorrhagic shock in rats. Acta Pharmacol Sin 2010; 31: 413-20.
96. 3 adenosine receptor in determining tissue levels of cAMP and blood pressure: Studies in knock-out mice. Biochim Biophys Acta 2000; 1500: 280-290.
97. 3 receptor agonist 2-Cl-IB-MECA in conscious rats. Eur J Pharmacol 1996; 308: 311-4.
98. 3 adenosine receptor in mice. J Pharmacol Exp Ther 2011; 338: 711-7.
99. 3 receptors in rat brain. Mol Pharmacol 1995; 48:1038-45.
100. Shneyvays V, Zinman T, Shainberg A. Analysis of calcium responses mediated by the A(3) adenosine receptor in cultured newborn rat cardiac myocytes. Cell Calcium 2004; 36: 387-96.
101. 3 receptors in regulation of cardiomyocyte homeostasis after mitochondrial respiratory chain injury. Am J Physiol Heart Circ Physiol 2005; 88: H2792-801.
102. Gorza L, Menabo R, Vitadello M, Bergamini CM, Di Lisa F. Cardio myocyte troponin T immunoreactivity is modified by crosslinking resulting from intracellular calcium overload. Circulation 1996; 93:1896-904.
103. 3 receptor in pancreas using transgenic mice expressing jellyfish apoaequorin. Transgenic Res 2007; 16: 429-35.
104. 3 adenosine receptor in monocyte-derived dendritic cells and recombinant cells. Mol Pharmacol 2003; 63: 342-50.
105. 3 adenosine receptors decreases heart rate, preserves energetics, and protects ischemic hearts. Am J Physiol Heart Circ Physiol 2002; 283: H1562-8.
106. 3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. J Mol Cell Cardiol 2001; 33: 825-30.
107. 3 adenosine receptor activation and gene knockout in ischemic-reperfused mouse heart. Cardiovasc Res 2002; 53:147-55.
108. 3 adenosine receptor activation attenuates neutrophil function and neutrophil-mediated reperfusion injury. Am J Physiol 1999; 277: H1895-905.
109. 3 receptor activation protects the myocardium from reperfusion/reoxygenation injury. Am J Physiol Heart Circ Physiol 2002; 283: H1307-13.
110. 3 receptor agonist, IB-MECA. Eur J Pharmacol 2003; 477: 235-45.
111. 3 adenosine receptor agonist IB-MECA reduces myocardial ischemiareperfusion injury in dogs. Am J Physiol Heart Circ Physiol 2003; 285: H607-H613.
112. Weiss JN, Korge P, Honda HM, Ping P. Role of the mitochondrial permeability transition in myocardial disease. Circ Res 2003; 93: 292-301.
113. Park SS, Zhao H, Jang Y, Mueller RA, Xu Z. N6-(3-Iodobenzyl)- adenosine-5-Nmethylcarboxamide confers cardioprotection at reperfusion by inhibiting mitochondrial permeability transition pore opening via glycogen synthase kinase 3β. J Pharm Exp Ther 2006; 318: 124-31.
114. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial: The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999; 34:1711-720.
115. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. AMISTAD-II investigators a randomized, double-blinded, placebocontrolled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTADII). J Am Coll Cardiol 2005; 45:1775-80.
116. Cohen MV, Downey JM. Adenosine: Trigger and mediator of cardioprotection. Basic Res Cardiol 2008; 103: 203-15.
117. Peart JN, Headrick JP. Adenosinergic cardioprotection: Multiple receptors, multiple pathways. Pharmacol Ther 2007; 114: 208-21.
118. Ashton KJ, Nilsson U, Willems L, Holmgren K, Headrick JP. Effects of aging and ischemia on adenosine receptor transcription in mouse myocardium. Biochem Biophys Res Commun 2003; 312: 367-72.
119. Linden J. Adenosine in tissue protection and tissue regeneration. Molecul Pharmacol 2005; 67: 1385-7.
120. 1 receptors ligands: past, present and future trends. Curr Topics Med Chem 2010; 9: 878-901.
121. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001; 414: 916-920.
122. Yan L, Burbiel JC, Maa A, Müller CE. Adenosine receptor agonists: From basic medicinal chemistry to clinical development. Expert Opin Emerg Drugs 2003; 8: 537-76.
123. Moro S, Gao ZG, Jacobson KA, Spalluto G. Progress in the pursuit of therapeutic adenosine receptor antagonists. Med Res Rev 2006; 26: 131-59.
124. Müller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochimica et Biophysica Acta (BBA) - Biomembranes 2011; 1808: 1290-308.
125. Kenneth A. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets-Nature Rev Drug Discov 2006; 5:247-264.
126. Fredholm BB, Ijzerman AP, Jacobson KA, Linden J, Müller CE. International Union of Basic and Clinical Pharmacology. LXXXI. nomenclature and classification of adenosine receptors. Update- Pharmacolog Rev 2011; 63:1-34.
127. 2A Receptor antagonists and Parkinson's disease. ACS Chem. Neurosci. 2011; 2: 555-67.
128. Kelland NF, Webb DJ. Clinical trials of endothelin antagonists in heart failure. Heart 2007; 93:2-4.
129. 1 receptor mediates delayed cardioprotective effect of sildenafil in mouse. J Molecul Cellular Cardiol 2007; 43: 545-51.
130. 1 adenosine receptors on postischemic cardiac function and expression of adenosine receptor subtypes. Am J Physiol Heart Circ Physiol 2006; 291: H1875-82.
131. 2A receptor. Nature 1997; 388: 674-8.
132. 2 adenosine receptors. J Pharmacol Exp Ther 2005; 315: 1150-7.
133. 2B receptors mediate antimitogenesis in ascular smooth muscle cells Hypertension 2000, 35: 267-72.
134. 1 receptor-mediated cardioprotection. Am J Physiol Heart Circ Physiol 2011; 301: H1183-9.
135. Roa H, Gajardo C, Troncoso E, Fuentealba V, Escudero C, Yáñez A, et al. Adenosine mediates transforming growth factor-beta 1 release in kidney glomeruli of diabetic rats. FEBS Lett 2009; 583: 3192-8.
136. Jacobson, K.A., Tosh, D.K. Methanocarbo adenosine derivatives and dendrimer conjugates thereof. WO2011068978 (2011).
137. Nell, P., Vakalopoulos, A., Sussmeier, F., Albrecht-Kupper, B, Zimmermann, K, Keldenich, J, Meibom, D. Substituted azabicyclic compounds and the use thereof. US20110003845 (2011).
138. 1 adenosine receptor agonists. US7825126 (2005).
139. 1 receptor agonists and methods. EP2221307 (2010).
140. 3 adenosine receptor: Pharmacology and role in disease. Hand book Exp Pharmacol 2009; 297-327.
141. Gao, ZG, Jacobson KA. Emerging adenosine receptor agonists. Expert Opin Emerg Drugs 2007; 12: 479-92.
142. 3 receptor agonist and cerebral ischemia: Neuronal and glial effects. Eur J Pharmacol 1999; 367:157-63.
143. von Lubitz, DK, Lin RC, McKenzie RJ, Devlin TM, McCabe RT, Skolnick P. A novel treatment of global cerebral ischaemia with a glycine partial agonist. Eur J Pharmacol 1992; 219:153-8.
144. 1 receptor agonist and antagonist on spatial learning and memory. Eur J Pharmacol 1993; 249: 271-80.
145. Xu Z, Jang Y, Mueller RA, Norfleet EA. IB-MECA and cardioprotection. Cardiovasc Drug Rev 2006; 24: 227-38.
146. Gao ZG, Kim SK, Biadatti T, Chen W, Lee K, Barak D, et al. Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary. J Med Chem 2002; 45: 4471-84.
147. 3 adenosine receptors. Curr Top Med Chem 2005; 5:1275-95.
148. Mekenyan O. Dynamic QSAR techniques: applications in drug design and toxicology. Curr Pharm Des 2002; 8:1605-21.
149. Perkins R, Fang H, Tong W, Welsh WJ. Qualtitative structureactivity relationship methods: Perspectives on drug discovery and toxicology. Environmental Toxicology and Chemistry 2003; 22:1666-79.
150. 3 adenosine receptor as a target to treat rheumatoid arthritis: Data from a phase II clinical trial. J Rheumatol 2008; 35: 41-8.
151. 1 adenosine receptor agonist and methods of use thereof. EP1758596B9 (2010).
152. Feldman, A., Chan, T. Composition and methods for the treatment of prevention and cardiovascular disease. WO2009076580 (2009).
153. 3 receptor gene sequence for predictive disease outcome and treatment outcome. WO2009058238 (2009).